| RRC ID |
41901
|
| Author |
Ito A, Tanaka K, Kondo K, Shinkai M, Honda H, Matsumoto K, Saida T, Kobayashi T.
|
| Title |
Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.
|
| Journal |
Cancer Sci
|
| Abstract |
Immunotherapy (IT) has become an accepted therapeutic modality. We previously reported that intracellular hyperthermia (IH) using magnetic nanoparticles induces antitumor immunity. We undertook these studies in order to study the combined effects of IT and IH on melanoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into a B16 melanoma nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the tumor reached 43 degrees C and was maintained by controlling the magnetic field intensity. At 24 h after IH, interleukin-2 (IL-2) or granulocyte macrophage-colony stimulating factor (GM-CSF) was injected directly into the melanoma. Mice were divided into six groups: group I (control), group II (IH), group III (IL-2), group IV (GM-CSF), group V (IH + IL-2), and group VI (IH + GM-CSF). Complete regression of tumors was observed in mice of groups V and VI (75% (6/8) and 40% (4/10) of the mice, respectively), while no tumor regression was observed in mice of the other groups. This study supports the combined use of IT and IH using MCLs in patients with advanced malignancies.
|
| Volume |
94(3)
|
| Pages |
308-13
|
| Published |
2003-3-1
|
| DOI |
10.1111/j.1349-7006.2003.tb01438.x
|
| PMID |
12824927
|
| MeSH |
Animals
Combined Modality Therapy
Disease Models, Animal
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
HSP70 Heat-Shock Proteins / analysis
Hyperthermia, Induced*
Immunotherapy / methods*
Interleukin-2 / therapeutic use
Magnetics
Melanoma, Experimental / immunology
Melanoma, Experimental / pathology
Melanoma, Experimental / therapy*
Mice
Mice, Inbred C57BL
Recombinant Proteins
Survival
Time Factors
Tumor Cells, Cultured
|
| IF |
4.966
|
| Times Cited |
118
|
|
WOS Category
|
ONCOLOGY
|
| Resource |
| Human and Animal Cells |
B16 melanoma 4A5(RCB0557) |
